Glycine, CAS# 56-40-6, is a proteinogenic amino acids manufactured through chemical synthesis from chloroacetic acid and ammonia, available as White Crystals or crystalline powder. Glycine is widely used as nutritional supplements. It is affirmed by US FDA as GRAS(generally recognized as safe) and widely accepted as safe food additive in many countries with E number E640.
nausea, vomiting, upper digestive tract discomfort, and mild drowsiness.
As Glycine is widely known as safe, there is no limit on dosage of intake. However, we still recommend consumers to consult professionals before using large quantity of Glycine for long period.
Special groups refer to newborns, children, pregnant and any other applicable vulnerable groups.
There is no evidence that Glycine could have any negative effects on these vulnerable groups. It should be safe to use Glycine in food for newborns and pregnant. However, we still recommend consumers to consult professionals before using large quantity of Glycine for long period in food for newborns or pregnant.
Generally recognized as safe(GRAS) is a FDA designation that a specific substance or ingredient is generally considered safe by experts, and so is exempted from the usual Federal Food, Drug, and Cosmetic Act (FFDCA) food additive tolerance requirements. Glycine is considered safe by FDA according to existing data and granted GRAS status.
No breaking news or public health crises reported about Glycine reported up to now.
* Want to report news about this ingredient, please send email to foodchemmis08@foodchem.cn. Your knowledge can help us to uncover more truthes about food ingredients to customers.
1. [Augmentation of antipsychotics with glycine may ameliorate depressive and extrapyramidal symptoms in schizophrenic patients--a preliminary 10-week open-label study]. [Psychiatr Pol. 2013 Jul-Aug]
Author: Strzelecki D, Kropiwnicki P, Rabe-Jabłońska J.
2. Glycine administration attenuates skeletal muscle wasting in a mouse model of cancer cachexia. [Clin Nutr. 2014 Jun]
Author: Ham DJ, Murphy KT, Chee A, Lynch GS, Koopman R.
3. [Changes in positive and negative symptoms, general psychopathology in schizophrenic patients during augmentation of antipsychotics with glycine: a preliminary 10-week open-label study]. [Psychiatr Pol. 2011 Nov-Dec]
Author: Strzelecki D, Rabe-Jabłońska J.
4. Effects of sarcosine, a glycine transporter type 1 inhibitor, in two mouse seizure models. [Pharmacol Rep. 2010 Mar-Apr]
Author: Socała K, Nieoczym D, Rundfeldt C, Wlaź P.